louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT02916784: Sit-to-stand in Spinal Cord Injury Patient
Official title: Relationship Between Ability of Sit-to-stand and Types of Walking Device Used in Ambulatory Patients With Spinal Cord Injury
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Injuries, Spinal Cord
Keywords: Sit-to-stand
Walking devices
Lead sponsor: Khon Kaen University
Sponsor class: OTHER
First posted: 2016-09-27
Enrollment: 69
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CROSSOVER
Time perspective: CROSS_SECTIONAL
Sampling method: PROBABILITY_SAMPLE
Study population: The study is conducted in subjects with incomplete spinal cord injury (iSCI) who are able to walk independently with or without an ambulatory assistive device (AAD) from the Srinagarind hospital, KhonKaen University, Thailand.

Brief summary: 1. Were there differences in functional ability between ambulatory individuals with SCI who passed and failed the independent sit-to-stand (iSTS) task?
2. Did the ability of iSTS relate to ability of walking as determined using a type of AAD used?
3. What were factors associated with the ability of iSTS?

Detailed description: * To evaluate the proportion and compare functional abilities between subjects who passed and failed the independent sit-to-stand (iSTS) task.
* To assess the relationship between ability of iSTS and types of AAD used.
* To investigate factors associated with the ability of iSTS.

Eligibility criteria: Inclusion Criteria:

* Ambulatory patients with iSCI from both non-traumatic and traumatic causes
* Aged at least 18 years
* Who are able to walk independently with or without AADs at least 15 meters continuously \[FIM locomotor (FIM-L) scores = 5 to 7\]

Exclusion Criteria:

* Any patients with conditions that might affect ambulatory ability; such as brain function disorders, visual deficits, musculoskeletal pain (VAS \> 5), deformity of the musculoskeletal system, unable to follow a command of the tests, unstable medical conditions.

Primary outcomes:
measure: Independent sit-to-stand test
timeFrame: 1 day
Secondary outcomes:
measure: Lower limb support during sit-to-stand test
timeFrame: 1 day
measure: Timed up and go test
timeFrame: 1 day
Other outcomes:
Locations:
Study officials:
affiliation: School of Physical Therapy, Faculty of Associated Medical Sciences, Khon Kaen University, Khon Kaen, Thailand.
name: Sugalya - Amatachaya, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00726284: Spine Patient Outcomes Registry for Biomet/EBI (Electro-Biology, Inc)
Official title: BIOMET/EBI (Electro-Biology, Inc) Spine Patient Outcomes Registry
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Degenerative Disc Disease
Spinal Stenosis
Keywords: Herniated nucleus pulposus (HNP)
Lead sponsor: Zimmer Biomet
Sponsor class: INDUSTRY
First posted: 2008-07-31
Enrollment: 651
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: This is an open cohort prospective patient registry conducted at multiple clinical centers

Brief summary: The purpose of this patient registry is to prospectively collect data on patients who are having spinal surgery with EBI and Interpore Cross Spine Products.

Detailed description: A patient registry to prospectively collect data on patients who are having spinal surgery with EBI and Interpore Cross Spine Products.

Eligibility criteria: Inclusion Criteria:

N/A

Exclusion Criteria:

N/A

Primary outcomes:
measure: Fusion Status
timeFrame: 24 Months
Secondary outcomes:
measure: Mean VAS (Visual Analog Scale) Score Change from baseline
timeFrame: 24 Month
measure: Oswestry Disability Index / Neck Disability Index (which ever is appropriate for the subject) change from baseline
timeFrame: 24 Month
measure: neurologic Assessment - maintenance or Improvement
timeFrame: 24 Month
measure: SF-36 (Short Form Survey-36) Health Outcomes - Change from Baseline
timeFrame: 24 Month
Other outcomes:
Locations:
city: Little Rock
country: United States
facility: Neurological Surgery Associates
state: Arkansas
city: Orange City
country: United States
facility: Florida Orthopedics Association
state: Florida
city: Akron
country: United States
facility: CNS Healthcare
state: Ohio
city: Tulsa
country: United States
facility: Oklahoma Spine and Brain
state: Oklahoma
city: Pottstown
country: United States
facility: Pottstown Memorial Medical Center
state: Pennsylvania
Study officials:
affiliation: EBI, LLC dba Biomet Spine, Biomet Trauma, Biomet Osteobiologics and Biomet Bracing
name: John Evangelsita, MD
role: STUDY_DIRECTOR
References:
Clinical trial NCT04613284: Rh-Endostatin Combined With CCRT(50 Gy) Followed by Durvalumab Maintenance for the Treatment of Specific Phase III NSCLC
Official title: Rh-Endostatin Combined With Low-dose CCRT(50 Gy) Followed by Durvalumab Maintenance for the Treatment of Specific Phase III NSCLC Who Can Not Tolerate 60 Gy Irradiation
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE4
Conditions: Lung Cancer
Lead sponsor: Shanghai Chest Hospital
Sponsor class: OTHER
Collaborators: name: Wuhan University
First posted: 2020-11-03
Enrollment: 97
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: A Study to Assess the Effects of Durvalumab following Rh-Endostatin combined with reduced-dose CCRT(50 Gy) in Patients with Stage III Unresectable Non-Small Cell Lung Cancer who can not tolerate 60 Gy irradiation.

Detailed description: A Phase II, Single-arm, Multi-centre Study of Durvalumab as Sequential Therapy in Patients with Locally Advanced, Unresectable Non-Small Cell Lung Cancer (Stage III) Who Have Not Progressed Following Rh-Endostatin combined with reduced-dose CCRT(50 Gy) Therapy (Relief)

Eligibility criteria: Inclusion Criteria:

* Age at 18-75 years.
* Documented evidence of NSCLC (locally advanced, unresectable, Stage III)
* Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST)
* Eastern Cooperative Oncology Group performance status score (ECOG PS) of 0 to 1.
* Estimated life expectancy of more than 12 weeks.

Exclusion Criteria:

* Prior exposure to any anti-PD-1 or anti-PD-L1 antibody.
* Active or prior autoimmune disease or history of immunodeficiency.
* Evidence of severe or uncontrolled systemic diseases, including active bleeding diatheses or active infections including hepatitis B, C and HIV.
* Evidence of uncontrolled illness such as symptomatic congestive heart failure, uncontrolled hypertension or unstable angina pectoris.
* Any unresolved toxicity CTCAE \>Grade 2 from the prior chemoradiation therapy.
* Active or prior documented inflammatory bowel disease (eg, Crohn's disease, ulcerative colitis).

Primary outcomes:
measure: Progression Free Survival
timeFrame: up to approximately 3 years
measure: adverse events (AE)
timeFrame: 5 years from patient enrollment
Secondary outcomes:
measure: Overall Survival
timeFrame: up to 5 years from patient enrollment
measure: Objective Response Rate
timeFrame: Tumor scans performed at baseline then every ~8 weeks up to 48 weeks, then every ~ 12 weeks thereafter up to 3 three years
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT00736502: PMS Assessing the Long-term Efficacy and Safety of Nevirapine Therapy (Combined With Other ARV Drugs) in HIV-1 Positive Patients in Daily Clinical Practice.
Official title: Longterm Efficacy and Safety of NVP-based HAART in HIV-1 Positive Patients in the Daily Clinical Practice.
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: HIV Infections
Lead sponsor: Boehringer Ingelheim
Sponsor class: INDUSTRY
First posted: 2008-08-18
Enrollment: 280
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: patients

Brief summary: The aim of this trial is to evaluate the safety and virological and immunological efficacy of Viramune® on a background of different antiretroviral drug combinations.


Eligibility criteria: Inclusion criteria:

The inclusion criteria follow the same criteria which are describe in the newest SPC.

Exclusion criteria:

The exclusion criteria follow the same criteria which are describe in the newest SPC.

Primary outcomes:
measure: Proportion of Patients Reporting Adverse Events
timeFrame: 48 weeks
Secondary outcomes:
measure: Virologic Response (VR)
timeFrame: 48 weeks
measure: Change in CD4+ Cell Count From Baseline to Week 48
timeFrame: Baseline and week 48
Other outcomes:
Locations:
city: Graz
country: Austria
facility: Boehringer Ingelheim Investigational Site 1
city: Linz
country: Austria
facility: Boehringer Ingelheim Investigational Site 2
city: Salzburg
country: Austria
facility: Boehringer Ingelheim Investigational Site 3
city: Vienna
country: Austria
facility: Boehringer Ingelheim Investigational Site 4
city: Vienna
country: Austria
facility: Boehringer Ingelheim Investigational Site 5
city: Vienna
country: Austria
facility: Boehringer Ingelheim Investigational Site 6
city: Wels
country: Austria
facility: Boehringer Ingelheim Investigational Site 7
city: Bialystok
country: Poland
facility: Boehringer Ingelheim Investigational Site 8
city: Bydgoszcz
country: Poland
facility: Boehringer Ingelheim Investigational Site 9
city: Chorzów
country: Poland
facility: Boehringer Ingelheim Investigational Site 10
city: Gdansk
country: Poland
facility: Boehringer Ingelheim Investigational Site 11
city: Kraków
country: Poland
facility: Boehringer Ingelheim Investigational Site 12
city: Lódz
country: Poland
facility: Boehringer Ingelheim Investigational Site 13
city: Poznan
country: Poland
facility: Boehringer Ingelheim Investigational Site 14
city: Szczecin
country: Poland
facility: Boehringer Ingelheim Investigational Site 15
city: Warszawa
country: Poland
facility: Boehringer Ingelheim Investigational Site 16
city: Wroclaw
country: Poland
facility: Boehringer Ingelheim Investigational Site 17
Study officials:
affiliation: Boehringer Ingelheim
name: Boehringer Ingelheim
role: STUDY_CHAIR
References:
Clinical trial NCT02144402: Growth of Healthy Term Infants Fed Formula Containing DHA-B
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Growth
Tolerance
Infant Development
Lead sponsor: DSM Nutritional Products, Inc.
Sponsor class: INDUSTRY
Collaborators: name: Accelovance
First posted: 2014-05-22
Enrollment: 159
Sex: ALL
Minimum age (years): 1
Maximum age (years): 14
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The primary objective is to determine if the weight gain of healthy term infants fed a commercially available term infant formula supplemented with DHASCO® is similar to that of infants fed the same formula supplemented with a new product, DHASCO®-B.


Eligibility criteria: Inclusion Criteria:

* full term infant (gestational age 37-42 weeks)
* birth weight \> or equal to 2500 g
* singleton infant \< or equal to 14 days of age in good health
* parent must be \>21 years of age
* parental consent

Exclusion Criteria:

* congenital malformation or genetic disorder
* metabolic anomalies
* maternal infectious diseases, alcoholism, substance abuse
* mothers with gestational diabetes
* participation in another clinical study

Primary outcomes:
measure: weight gain (gm/day)
timeFrame: through day of life 120
Secondary outcomes:
measure: length (cm)
timeFrame: through day of life 120
measure: head circumference (cm)
timeFrame: through day of life 120
measure: fatty acid levels (wgt %)
timeFrame: at day of life 120
measure: Formula intake and tolerance
timeFrame: Day of life 30 and 120
Other outcomes:
measure: adverse events
timeFrame: through day of life 120
Locations:
city: Dothan
country: United States
facility: Claude Ashley, MD
state: Alabama
city: Jonesboro
country: United States
facility: JBRKIDS
state: Arkansas
city: Norwich
country: United States
facility: Norwich Pediatric
state: Connecticut
city: St Petersburg
country: United States
facility: Score Physician Alliance
state: Florida
city: Wellington
country: United States
facility: Atlantic Clinical Research
state: Florida
city: Newburgh
country: United States
facility: Pedia Research
state: Indiana
city: Wichita
country: United States
facility: Heartland Research
state: Kansas
city: Fall River
country: United States
facility: Stephen Kasparian
state: Massachusetts
city: Lincoln
country: United States
facility: MCHRI
state: Nebraska
city: Dayton
country: United States
facility: Ohio Pediatric Research
state: Ohio
Study officials:
References:
Clinical trial NCT00466479: Brimonidine vs ALTP in Progressing Human Glaucoma
Official title: Topical Brimonidine vs Argon Laser Trabeculoplasty in Progressing Human Glaucoma. A Prospective Randomized Clinical Trial.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Glaucoma
Keywords: neuroprotection
alpha one agonists
glaucoma
visual field
Lead sponsor: University of Parma
Sponsor class: OTHER
First posted: 2007-04-27
Enrollment: 50
Sex: ALL
Minimum age (years): 50
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study is evaluating possible non-intraocular pressure (IOP) related effects of the alpha-1 agonist brimonidine in human subjects affected by a progressive glaucomatous optic neuropathy. Brimonidine was proven as neuroprotective in several pre-clinical animal studies.

Detailed description: Patients with open angle glaucoma and a history of relative stability of the visual field are followed for 18 months. A visual field is measured every 3 months for a total number of n = 6 eligible fields at the end of this phase. Then, those eyes showing progression of the field (i.e. deterioration of th eexisting glaucoma), are randomized to receive either 0.2% brimonidine tartrate eyedrops b.i.d. or 360° argon laser trabeculoplasty in one session. Either treatment will be put "on top" of the pre-existing anti-glaucoma therapy. Then, a further 18-month phase is planned, with a sequnece of field taken at the same pace as the previous phase. Progression is detected (and measured) acording to a trend-analysis (i.e. regression vs time of single points and of clusters of adjacent points).

Eligibility criteria: Inclusion Criteria:

* Glaucomatous visual field defect on achromatic perimetry (24/2 Humphrey full threshold,abnormal GHT and CPSD, p\<0.01) considered clinically "unstable"
* IOP \< 20 mmHg on repeated readings with no more than 2 medications,
* Open angle on gonioscopy,
* Glaucomatous optic neuropathy (HRTII, Moorfields regression analysis),
* Clear lens (LOCS2 score \< C1, N0, P0)
* Best corrected visual acuity better than 0.2 LogMAR (ETDRS chart),
* No previous bulbar surgery
* Manifest refraction within - 5 and + 2 diopters
* No comorbidity (AMD and diabetic retinopathy.and negative history for neurological diseases)

Exclusion Criteria:

* Closed angle
* Previous bulbar surgery
* Unstable IOP
* Unreliable visual fields on historic data

Primary outcomes:
measure: progression of visual field measured as loss of sensitivity in decibels per year
measure: progression of visual field measured as number of eyes showing at least one cluster of points progressing
Secondary outcomes:
measure: number of drop out(s) for adverse events
Other outcomes:
Locations:
city: Parma
country: Italy
facility: sezione di Oftalmologia
Study officials:
affiliation: University of Parma
name: stefano gandolfi, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01367379: The Effect of the Duty Loading on the Stress Response of Physician
Official title: The Effect of the Duty Loading on the Stress Response of Physician
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Physiological Stress
Psychological Stress
Keywords: Physician
duty loading
stress response
Physician with different amount of duty area
Lead sponsor: National Taiwan University Hospital
Sponsor class: OTHER
Collaborators: name: Taipei City Hospital
First posted: 2011-06-07
Enrollment: 15
Sex: MALE
Minimum age (years): 30
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CROSSOVER
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Attending physicians of internal medicine of Taipei municipal hospital, certified by Taiwan society of internal medicine. We will compare those results of outcome variables of different amount of duty area.

Brief summary: The investigators will study in the possibility of cardiovascular disease, caused by the duty loading, of physician of internal medicine. The investigators will also explore if there {dose response effect} between the duty loading and the stress response of physicians of internal medicine. Therefore, the investigators will compare the stress responses of physicians of internal medicine during with different duty loading ( non-duty day, one duty area with 3 wards, 2 duty areas with 6 wards) in a observational method. Those stress response will be measured by cardiovascular risk indicators, including blood pressure, heart rate variability, blood sampling and urine sampling.


Eligibility criteria: Inclusion Criteria:

* Attending physicians of internal medicine of Taipei municipal hospital, certified by Taiwan society of internal medicine.

Exclusion Criteria:

* thyroid dysfunction
* pregnancy, diabetes mellitus
* history of cardiovascular disease (stroke, coronary arterial disease, or myocardial infraction)
* current smokers, or
* taking sleeping pills or B-blocker

Primary outcomes:
measure: The physiological change of physician during different duty loadings
timeFrame: 4 months
Secondary outcomes:
Other outcomes:
Locations:
city: Taipei
country: Taiwan
facility: National Taiwan university hospital
Study officials:
affiliation: National Taiwan University Hospital
name: Yue Leon Guo, Professor
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01336179: Comparative Effect of Chewing Sticks and Toothbrushing on Plaque Removal and Gingival Health
Official title: The Efficacy of the Miswak Chewing Sticks (Salvadora Persica)on Plaque Removal and Gingival Health: Randomised Clinical Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Plaque Induced Gingivitis
Keywords: gingivitis
dental plaque
oral hygiene
toothbrush
chewing sticks
Lead sponsor: Taibah University
Sponsor class: OTHER
First posted: 2011-04-15
Enrollment: 18
Sex: MALE
Minimum age (years): 20
Maximum age (years): 30
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of the proposed study is to compare the effect of chewing sticks (Miswak) and the toothbrushes on plaque removal and gingival health.

Detailed description: Dental plaque removal is essential in maintaining oral health. Methods for oral hygiene vary from country to country and from culture to culture. The use of a wood stick (miswak or chewing stick) for brushing the teeth is considered an important tool for oral hygiene care in many Afro-Asian communities. The aim of the study is to compare the effect of the chewing stick (miswak), and toothbrushing on plaque removal and gingival health. The participants comprise 18 healthy Saudi Arabian male volunteers aged 21 to 30 years, at Taibah University in Saudi Arabia. The study was designed as a single, blind, randomized split-mouth study. Professional tooth cleaning was conducted, and after six weeks use of either the miswak or toothbrush on each quadrant, modified plaque and gingival indices, were recorded.

Eligibility criteria: Inclusion Criteria:

* Healthy individuals
* presence of at least 14 teeth

Exclusion Criteria:

* Subjects on medications (antiinflammatory or antibiotics)

Primary outcomes:
measure: Miswak is useful for removing plaque and preventing gingivitis
timeFrame: 6 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Almadinah
country: Saudi Arabia
facility: Faculty of Dentistry Taibah University
Study officials:
affiliation: Assistant professor in Periodontics, Taibah University
name: Tareq AS Abu Saleh, MSc, MRD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02759679: Canine-Assisted Profiling of Lung Cancer From Human Breath
Official title: Canine-Assisted Profiling of Lung Cancer From Human Breath
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Lung Cancer
Lead sponsor: Haukeland University Hospital
Sponsor class: OTHER
First posted: 2016-05-03
Enrollment: 650
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: The study aims to optimize and define a reproducible and non-invasive method for canine assisted lung cancer detection, using human breath samples from patients and controls for training and testing purposes.


Eligibility criteria: Inclusion criteria:

Healthy volunteers, lung cancer or other lung disease.

Exclusion criteria:

Other known malignancy.

Primary outcomes:
measure: Sensitivity and specificity for lung cancer, of canines sniffing breath samples
timeFrame: 2 years
Secondary outcomes:
Other outcomes:
Locations:
city: Bergen
country: Norway
facility: Haukeland University Hospital
Study officials:
affiliation: Haukeland University Hospital, Bergen, Norway
name: Øystein Fløtten, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06933979: Positional Changes of Mandibular Molar After Orthodontic Treatment
Official title: Changes in the Position of Mandibular Third Molar in Orthodontically Treated Patients With First Premolars Extraction
Study type: OBSERVATIONAL
Overall status: ACTIVE_NOT_RECRUITING
Conditions: Third Molar
Keywords: orthodontic treatment
premolar extraction
Lead sponsor: Fayoum University
Sponsor class: OTHER
First posted: 2025-04-18
Enrollment: 30
Sex: ALL
Minimum age (years): 14
Maximum age (years): 18
Standard ages: CHILD
ADULT
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Sample size calculation estimated the minimum total required sample size (n) was found to be (27). The sample size was increased to (30) account for sample variability and to improve the robustness of statistical testing

Brief summary: This retrospective study was carried out on pre and posttreatment digital standardized panoramic radiographs of 30 cases previously orthodontically treated with four first premolar extraction.


Eligibility criteria: Inclusion Criteria:

- class I malocclusion cases (0 \< ANB \< 4) with moderate crowding

Exclusion Criteria:

* Absence of all permanent teeth including mandibular third molars.

Primary outcomes:
measure: Assessment of mandibular third molar positional variation
timeFrame: 2 years
Secondary outcomes:
Other outcomes:
Locations:
city: Fayoum
country: Egypt
facility: Fayoum University
Study officials:
affiliation: lecturer of orthodontics, faculty of dentistry, Fayoum university
name: Shereen A Mahlawy, PHD
role: PRINCIPAL_INVESTIGATOR
affiliation: Clinical trials.gov
name: clinical cT trial
role: STUDY_DIRECTOR
References:
citation: Zarin DA, Tse T, Williams RJ, Califf RM, Ide NC. The ClinicalTrials.gov results database--update and key issues. N Engl J Med. 2011 Mar 3;364(9):852-60. doi: 10.1056/NEJMsa1012065.